(Q33397838)

26 July 2017

0 references

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis (English)

1 reference

26 July 2017

1 reference

ChEBI release 2020-05-28

1 reference

1

Ayalew Tefferi

1 reference

26 July 2017

Animesh Pardanani

2

1 reference

PubMed ID

22034658

26 July 2017

language of work or name

English

0 references

publication date

27 October 2011

1 reference

26 July 2017

1 reference

26 July 2017

86

1 reference

26 July 2017

1188-1191

1 reference

26 July 2017

12

1 reference

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

26 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

How I treat myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

Pathogenesis of myelofibrosis with myeloid metaplasia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3228619

Myelofibrosis with myeloid metaplasia

21 June 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22034658

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term outcome of treatment with ruxolitinib in myelofibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22034658

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22034658

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4065/MCP.2011.0518

1 reference

26 July 2017

1 reference

26 July 2017

1 reference

PubMed ID

22034658